FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4225528825> ?p ?o ?g. }

• W4225528825 endingPage "759" @default.
• W4225528825 startingPage "751" @default.
• W4225528825 abstract "Sunitinib is an oral tyrosine kinase inhibitor approved for the treatment of metastatic renal cell carcinoma (mRCC). High variability in pharmacokinetics coupled with a proven exposure–effect relationship makes sunitinib an ideal candidate for therapeutic drug monitoring (TDM). The feasibility of TDM of sunitinib in patients with mRCC was evaluated in this prospective observational study in a real-world scenario. Seventy patients with mRCC treated with sunitinib at a fixed dose of 50 mg per day were enrolled in the study. Total trough plasma level (TTL) of sunitinib (sunitinib and its active metabolite, SU12662), was measured between days 14/15 of cycle 1. The discriminatory potential of TTL of sunitinib for the prediction of responders and occurrence of grade ≥ 3 toxicity was determined using receiver operating characteristic (ROC) curve. The median TTL of sunitinib was 76 ng/mL. Forty six out of 70 patients were evaluable for response, whereas 60 out of 70 patients were evaluable for toxicity. Threshold concentrations obtained from ROC analysis showed that TTL of 60.75 ng/mL and 82.3 ng/mL was discriminatory for response and occurrence of grade ≥ 3 toxicity respectively. 31/34 (91.7%) patients having TTL ≥ 60.75 ng/mL responded to treatment, while only 5/12 (41.6%) responded when TTL was < 60.75 ng/mL (P = 0.001). On the other hand, the incidence of grade ≥ 3 toxicity was 9/24 (37.7%) in patients with TTL ≥ 82.3 ng/mL compared to 4/36 (11.1%) in patients with TTL < 82.3 ng/mL (P = 0.024). The TTL range of 60.75–82.3 ng/mL was found to be optimal in terms of safety and efficacy. More than 50% of patients in our cohort attained TTL of sunitinib outside the optimal range, thus demonstrating the feasibility of TDM to improve safety and efficacy of sunitinib in mRCC." @default.
• W4225528825 created "2022-05-05" @default.
• W4225528825 creator A5003412464 @default.
• W4225528825 creator A5019683977 @default.
• W4225528825 creator A5027531002 @default.
• W4225528825 creator A5036181677 @default.
• W4225528825 creator A5037405695 @default.
• W4225528825 creator A5041357286 @default.
• W4225528825 creator A5042508373 @default.
• W4225528825 creator A5044346237 @default.
• W4225528825 creator A5082030725 @default.
• W4225528825 creator A5085232314 @default.
• W4225528825 creator A5088151142 @default.
• W4225528825 date "2022-04-19" @default.
• W4225528825 modified "2023-10-08" @default.
• W4225528825 title "Feasibility of therapeutic drug monitoring of sunitinib and its implications on response and toxicity in patients with metastatic renal cell cancer" @default.
• W4225528825 cites W1946476244 @default.
• W4225528825 cites W1976575396 @default.
• W4225528825 cites W1989153896 @default.
• W4225528825 cites W1989535705 @default.
• W4225528825 cites W2016430469 @default.
• W4225528825 cites W2019607817 @default.
• W4225528825 cites W2021400076 @default.
• W4225528825 cites W2075775855 @default.
• W4225528825 cites W2097147116 @default.
• W4225528825 cites W2113788015 @default.
• W4225528825 cites W2117125017 @default.
• W4225528825 cites W2166456106 @default.
• W4225528825 cites W2166819037 @default.
• W4225528825 cites W2735359179 @default.
• W4225528825 cites W2805430385 @default.
• W4225528825 cites W2907132226 @default.
• W4225528825 cites W2946704805 @default.
• W4225528825 cites W2954331841 @default.
• W4225528825 cites W3000378167 @default.
• W4225528825 cites W3003901162 @default.
• W4225528825 cites W3160214478 @default.
• W4225528825 doi "https://doi.org/10.1007/s00280-022-04432-4" @default.
• W4225528825 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35441269" @default.
• W4225528825 hasPublicationYear "2022" @default.
• W4225528825 type Work @default.
• W4225528825 citedByCount "4" @default.
• W4225528825 countsByYear W42255288252022 @default.
• W4225528825 countsByYear W42255288252023 @default.
• W4225528825 crossrefType "journal-article" @default.
• W4225528825 hasAuthorship W4225528825A5003412464 @default.
• W4225528825 hasAuthorship W4225528825A5019683977 @default.
• W4225528825 hasAuthorship W4225528825A5027531002 @default.
• W4225528825 hasAuthorship W4225528825A5036181677 @default.
• W4225528825 hasAuthorship W4225528825A5037405695 @default.
• W4225528825 hasAuthorship W4225528825A5041357286 @default.
• W4225528825 hasAuthorship W4225528825A5042508373 @default.
• W4225528825 hasAuthorship W4225528825A5044346237 @default.
• W4225528825 hasAuthorship W4225528825A5082030725 @default.
• W4225528825 hasAuthorship W4225528825A5085232314 @default.
• W4225528825 hasAuthorship W4225528825A5088151142 @default.
• W4225528825 hasBestOaLocation W42255288252 @default.
• W4225528825 hasConcept C112705442 @default.
• W4225528825 hasConcept C121608353 @default.
• W4225528825 hasConcept C126322002 @default.
• W4225528825 hasConcept C126894567 @default.
• W4225528825 hasConcept C143998085 @default.
• W4225528825 hasConcept C2777288759 @default.
• W4225528825 hasConcept C2777472916 @default.
• W4225528825 hasConcept C2778820342 @default.
• W4225528825 hasConcept C2779490328 @default.
• W4225528825 hasConcept C2780272996 @default.
• W4225528825 hasConcept C29730261 @default.
• W4225528825 hasConcept C71924100 @default.
• W4225528825 hasConcept C76318530 @default.
• W4225528825 hasConcept C90924648 @default.
• W4225528825 hasConcept C98274493 @default.
• W4225528825 hasConceptScore W4225528825C112705442 @default.
• W4225528825 hasConceptScore W4225528825C121608353 @default.
• W4225528825 hasConceptScore W4225528825C126322002 @default.
• W4225528825 hasConceptScore W4225528825C126894567 @default.
• W4225528825 hasConceptScore W4225528825C143998085 @default.
• W4225528825 hasConceptScore W4225528825C2777288759 @default.
• W4225528825 hasConceptScore W4225528825C2777472916 @default.
• W4225528825 hasConceptScore W4225528825C2778820342 @default.
• W4225528825 hasConceptScore W4225528825C2779490328 @default.
• W4225528825 hasConceptScore W4225528825C2780272996 @default.
• W4225528825 hasConceptScore W4225528825C29730261 @default.
• W4225528825 hasConceptScore W4225528825C71924100 @default.
• W4225528825 hasConceptScore W4225528825C76318530 @default.
• W4225528825 hasConceptScore W4225528825C90924648 @default.
• W4225528825 hasConceptScore W4225528825C98274493 @default.
• W4225528825 hasFunder F4320320720 @default.
• W4225528825 hasIssue "6" @default.
• W4225528825 hasLocation W42255288251 @default.
• W4225528825 hasLocation W42255288252 @default.
• W4225528825 hasLocation W42255288253 @default.
• W4225528825 hasOpenAccess W4225528825 @default.
• W4225528825 hasPrimaryLocation W42255288251 @default.
• W4225528825 hasRelatedWork W1895933560 @default.
• W4225528825 hasRelatedWork W2074629895 @default.
• W4225528825 hasRelatedWork W2103529332 @default.
• W4225528825 hasRelatedWork W2367626691 @default.

• next